Core Viewpoint - The approval of a new indication for Sugli monoclonal antibody by the European Commission marks a significant advancement for the company, providing new treatment options for a broader patient population with advanced non-small cell lung cancer (NSCLC) [1] Group 1: Company Developments - 基石药业-B (02616) shares rose over 5%, specifically by 5.32%, reaching HKD 5.94 with a trading volume of HKD 8.2294 million [1] - The European Commission has approved Sugli monoclonal antibody for the treatment of adult patients with unresectable stage III non-small cell lung cancer (NSCLC) who have PD-L1 expression ≥1%, no EGFR sensitive mutations or ALK, ROS1 genomic alterations, and have not shown disease progression after platinum-based chemoradiotherapy [1] - The CEO of the company, Dr. Yang Jianxin, highlighted that this new indication approval comes just one year after the initial approval for Sugli monoclonal antibody for first-line treatment of metastatic squamous and non-squamous NSCLC, indicating comprehensive coverage from stage III to IV NSCLC in Europe [1]
港股异动 | 基石药业-B(02616)涨超5% 欧盟委员会已批准舒格利单抗的新适应症